The stock of NuCana plc ADR (NCNA) has seen a -23.79% decrease in the past week, with a -66.94% drop in the past month, and a -3.92% decrease in the past quarter. The volatility ratio for the week is 17.68%, and the volatility levels for the past 30 days are at 21.66% for NCNA. The simple moving average for the past 20 days is -29.01% for NCNA’s stock, with a -54.72% simple moving average for the past 200 days.
Is It Worth Investing in NuCana plc ADR (NASDAQ: NCNA) Right Now?
The 36-month beta value for NCNA is also noteworthy at 1.01. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NCNA is 1.98M, and at present, short sellers hold a 3.15% of that float. The average trading volume of NCNA on September 30, 2024 was 1.37M shares.
NCNA) stock’s latest price update
The stock of NuCana plc ADR (NASDAQ: NCNA) has decreased by -10.91 when compared to last closing price of 2.75.Despite this, the company has seen a loss of -23.79% in its stock price over the last five trading days. globenewswire.com reported 2024-09-25 that EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month.
Analysts’ Opinion of NCNA
Truist gave a rating of “Buy” to NCNA, setting the target price at $22 in the report published on October 22nd of the previous year.
NCNA Trading at -41.38% from the 50-Day Moving Average
After a stumble in the market that brought NCNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.90% of loss for the given period.
Volatility was left at 21.66%, however, over the last 30 days, the volatility rate increased by 17.68%, as shares sank -68.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.14% lower at present.
During the last 5 trading sessions, NCNA fell by -23.79%, which changed the moving average for the period of 200-days by -72.00% in comparison to the 20-day moving average, which settled at $3.19. In addition, NuCana plc ADR saw -66.87% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NCNA
The total capital return value is set at -8.47. Equity return is now at value -179.05, with -91.15 for asset returns.
Based on NuCana plc ADR (NCNA), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -61.61.
Currently, EBITDA for the company is -28.89 million with net debt to EBITDA at 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In summary, NuCana plc ADR (NCNA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
